Therapeutic Compositions for Endothelial Regeneration in ARDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) and COVID-19-related conditions, particularly in elderly patients, lack effective pharmacological and cell-based therapies, with high mortality rates and impaired endothelial regeneration and vascular repair mechanisms due to aging.
Innovation Solution
Administration of compounds such as N-acetyl cysteine, NOX2 inhibitors, Decitabine, and nanoparticles to inhibit endothelial injury and promote vascular repair, including combination therapies with FoxM1-expressing nucleic acids to enhance endothelial regeneration and vascular repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current supportive therapy is used for ARDS and COVID-19, then treatment simplicity is maintained, but mortality rate remains high at 40%
Solution Approach 1:
The treatment is divided into multiple sequential phases: acute phase treatment with anti-inflammatory agents, subacute phase with endothelial protection compounds, and recovery phase with regenerative therapies. Each phase targets specific pathophysiological processes, allowing complex treatment to be managed in discrete, manageable steps that can be administered through standard medical pathways
Solution Approach 2:
The patent introduces endothelial-protective compounds and regenerative agents as intermediary substances that mediate between the harmful viral effects and the body's natural repair mechanisms. These compounds act as biochemical intermediaries that amplify endogenous repair pathways while reducing exogenous intervention requirements
2Reliability
If elderly patients receive standard care for COVID-19, then treatment accessibility is maintained, but mortality rate increases to over 25%
Solution Approach 1:
The protocol initiates endothelial protection therapy within 24-48 hours of symptom onset, before severe vascular damage and thrombotic complications fully develop. This preliminary intervention prevents the cascade of endothelial injury that particularly affects elderly patients, addressing their reduced regenerative capacity before it can be fully exploited by the pathology
Solution Approach 2:
The treatment protocol adjusts dosing parameters and timing based on patient age and severity metrics. Elderly patients receive optimized dosing schedules that account for reduced metabolic clearance and diminished regenerative reserve, transforming the standard protocol into an age-adjusted regimen that maintains accessibility while improving outcomes
3Reliability
If endothelial injury is left untreated in COVID-19, then treatment simplicity is maintained, but vascular repair mechanisms fail leading to multi-organ failure
Solution Approach 1:
The treatment protocol maintains continuous therapeutic pressure on the endothelial repair pathway through staged administration of complementary agents. Anti-inflammatory therapy continues through the acute phase, endothelial protection compounds are maintained through the subacute phase, and regenerative agents are introduced in the recovery phase, creating an unbroken chain of therapeutic support that mirrors the continuous nature of endothelial repair
Solution Approach 2:
The patent combines multiple therapeutic modalities into a unified protocol: anti-inflammatory agents address cytokine storm, endothelial-protective compounds preserve vascular integrity, and regenerative therapies restore endothelial function. These distinct mechanisms are merged into a single coordinated protocol that can be administered through existing medical infrastructure
Data Source
AI summary
Disclosed herein are methods and compositions for treatment of COVID-19 and associated sepsis, respiratory distress and organ failure, acute respiratory distress syndrome, sepsis, infection-induced organ failure, restenosis, critical limb ischemia, and vascular diseases associated with impaired endothelial regeneration, vascular repair, and vascular regeneration. In some embodiments, the methods include administering an effective amount of one or more of a) Dexamethasone, Resveratrol, N-acetylcysteine, Apocynin, Ebselen, APX-115, NOX2 inhibiting peptide, NOX2 inhibiting nucleic acid, Thienopyridine, orb) Selisistat, AG-1031, rabeprazole, phenazopyridine, roxadustat, molidustat, vadadustat, desidustat, decitabine, azacytidine, and analogues thereof, FOXM1 expressing nucleic acid, HIF1A expressing nucleic acid, SIRT1 inhibiting nucleic acid, EGLN1 inhibiting nucleic acid, or c) combination of one of a with one of b to a subject in need thereof. In some embodiments, the monotherapy or combination therapy is particularly useful for treatment of an elderly subject, and is useful to treat a subject at any age.